Strength of patient cohorts and biobanks for cardiomyopathy research

R. A. de Boer, L. L.A.M. Nijenkamp, H. H.W. Silljé, T. R. Eijgenraam, R. Parbhudayal, B. van Driel, R. Huurman, M. Michels, J. Pei, M. Harakalova, F. H.M. van Lint, M. Jansen, A. F. Baas, F. W. Asselbergs, J. P. van Tintelen, B. J.J.M. Brundel, L. M. Dorsch, M. Schuldt, D. W.D. Kuster, J. van der Velden*DOSIS consortium

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

In 2011 the Netherlands Heart Foundation allocated funding (CVON, Cardiovasculair Onderzoek Nederland) to stimulate collaboration between clinical and preclinical researchers on specific areas of research. One of those areas involves genetic heart diseases, which are frequently caused by pathogenic variants in genes that encode sarcomere proteins. In 2014, the DOSIS (Determinants of susceptibility in inherited cardiomyopathy: towards novel therapeutic approaches) consortium was initiated, focusing their research on secondary disease hits involved in the onset and progression of cardiomyopathies. Here we highlight several recent observations from our consortium and collaborators which may ultimately be relevant for clinical practice.

Original languageEnglish
Pages (from-to)50-56
Number of pages7
JournalNetherlands Heart Journal
Volume28
DOIs
Publication statusPublished - 1 Aug 2020

Cite this